Details of imatinib therapy and responses
| UPN . | FEV1 before imatinib . | Maximum daily dose of imatinib, mg . | Duration of imatinib treatment, mo . | Side effects CTC > °2 . | FEV1 after imatinib . | Response* . | Outcome . |
|---|---|---|---|---|---|---|---|
| 763 | 24% | 200 | 16 | – | 20% | partial | alive |
| 824 | 36% | 200 | 10 | – | 45% | partial | alive |
| 1093 | 29% | 200 | 2 | – | 26% | none | died |
| 1307 | 32% | 100 | 1 | Dyspnea → withdrawal | 35% | none | alive |
| 1371 | 18% | 100 | 1 | – | 25% | none | died |
| 1466 | 25% | 400 | 17+ | – | 21% | none | alive |
| 1068 | 24% | 200 | 4 | – | 29% | none | alive |
| 736 | 41% | 400 | 4 | Dyspnea → withdrawal | 42% | none | alive |
| 1730 | 33% | 400 | 1+ | – | 21% | none | alive |
| UPN . | FEV1 before imatinib . | Maximum daily dose of imatinib, mg . | Duration of imatinib treatment, mo . | Side effects CTC > °2 . | FEV1 after imatinib . | Response* . | Outcome . |
|---|---|---|---|---|---|---|---|
| 763 | 24% | 200 | 16 | – | 20% | partial | alive |
| 824 | 36% | 200 | 10 | – | 45% | partial | alive |
| 1093 | 29% | 200 | 2 | – | 26% | none | died |
| 1307 | 32% | 100 | 1 | Dyspnea → withdrawal | 35% | none | alive |
| 1371 | 18% | 100 | 1 | – | 25% | none | died |
| 1466 | 25% | 400 | 17+ | – | 21% | none | alive |
| 1068 | 24% | 200 | 4 | – | 29% | none | alive |
| 736 | 41% | 400 | 4 | Dyspnea → withdrawal | 42% | none | alive |
| 1730 | 33% | 400 | 1+ | – | 21% | none | alive |
Pulmonary scoring according to FEV1 (% predicted) or lung function score (LFS)2: mild, FEV1 60%-79% or LFS 3-5; moderate, FEV1 40%-59% or LFS 6-9; and severe, FEV1 < 40% or LFS 10-12.
CTC > °2 indicates toxicities graded as greater than 2 according to the international Common Toxicity Criteria.
Response to imatinib treatment, as defined by Olivieri et al.1